Li Xiting

Li Xiting founded Mindray Medical in 1991 in Shenzhen and has built it into China's largest medical device company by market capitalization and one of the few Chinese medtech companies competing globally with Western multinationals. Mindray operates across three core segments: Patient Monitoring & Life Support (monitoring systems, defibrillators, anesthesia machines — where Mindray holds approximately 10% global market share), In-Vitro Diagnostics (hematology, biochemistry, immunoassay analyzers), and Medical Imaging (ultrasound systems). Li's strategy has been systematic: start by offering products at significantly lower price points than Western incumbents in emerging markets, then progressively improve quality and technology to compete in developed markets. This "value innovation" approach has allowed Mindray to capture market share in Southeast Asia, Latin America, Africa, and the Middle East, and increasingly in Europe and the US. The company invests over 10% of revenue in R&D and has built research centers in Shenzhen, Seattle, Silicon Valley, and Stockholm. Li's execution on international market share gains, new product innovation (particularly in AI-enhanced imaging and automated IVD systems), and Mindray's ability to close the technology gap with Siemens Healthineers and GE Healthcare are the primary drivers of the stock.